Meri Tarockoff1, Teresita Gonzalez1, Stanislav Ivanov1, Jose Sandoval-Sus2,3. 1. Department of Hematology and Oncology, Memorial Healthcare System, Hollywood, USA. 2. Department of Hematology and Oncology, Memorial Healthcare System, Hollywood, USA. jose.sandoval@moffitt.org. 3. Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System Memorial Cancer Institute, 603 N. Flamingo Rd., Suite 151, Pembroke Pines, FL, 33028, USA. jose.sandoval@moffitt.org.
Abstract
PURPOSE OF REVIEW: In this review, the current treatment strategies are recapped, evolving agents are discussed, and we provide guidance in treating R/R MCL. RECENT FINDINGS: There has been an advancement in treatment using targeted therapy, cellular therapies including chimeric antigen receptor (CAR) T cell therapy and hematopoietic stem cell transplantation (HSCT) and novel therapeutic agents including non-covalent BTKis, bispecific antibodies, and antibody-drug conjugates for treatment of refractory and relapsed mantle cell lymphoma. Mantle cell lymphoma (MCL) is a mature B-cell lymphoma that is associated with a poor prognosis. Current treatments include immunochemotherapy, chemotherapy and autologous stem cell transplantation (SCT) which place patients in remission but result in relapse. Chemoimmunotherapy uses chemotherapeutic agents paired with rituximab in patients who have chemo-sensitive disease with prolonged remission of at least > 2 years and/or have contraindications to chemotherapy that serve as bridges to more definitive treatment. Additional therapies including proteosome inhibitor-based therapies and immunomodulators, like bortezomib and lenalidomide, can be used as single agents or in combination with others. Bruton's tyrosine kinase (BTK) inhibitors including ibrutinib, acalaburtinib, and zanubrutinib have also been proven effective for the treatment of (R/R) disease. Another agent is Venetoclax, a robust drug that can be used in MCL after progression or intolerance to BTKi. Newer advances in the management of MCL have led to the utilization of cellular therapies including chimeric antigen receptor (CAR) T cell therapy and SCT that are options for healthy young (< 65 years old) who have progressed through several lines of therapies. With progression of disease, mutations are acquired that cause therapy resistance. Novel therapeutic agents such as non-covalent BTKis, bispecific antibodies, and antibody-drug conjugates are paving the way for advancements in treatment for R/R MCL. R/R MCL is a complex disease with many therapeutic options none of which has been proven superior in head-to-head comparison. In this review, the current treatment strategies are recapped, evolving agents are discussed, and we provide guidance in treating R/R MCL.
PURPOSE OF REVIEW: In this review, the current treatment strategies are recapped, evolving agents are discussed, and we provide guidance in treating R/R MCL. RECENT FINDINGS: There has been an advancement in treatment using targeted therapy, cellular therapies including chimeric antigen receptor (CAR) T cell therapy and hematopoietic stem cell transplantation (HSCT) and novel therapeutic agents including non-covalent BTKis, bispecific antibodies, and antibody-drug conjugates for treatment of refractory and relapsed mantle cell lymphoma. Mantle cell lymphoma (MCL) is a mature B-cell lymphoma that is associated with a poor prognosis. Current treatments include immunochemotherapy, chemotherapy and autologous stem cell transplantation (SCT) which place patients in remission but result in relapse. Chemoimmunotherapy uses chemotherapeutic agents paired with rituximab in patients who have chemo-sensitive disease with prolonged remission of at least > 2 years and/or have contraindications to chemotherapy that serve as bridges to more definitive treatment. Additional therapies including proteosome inhibitor-based therapies and immunomodulators, like bortezomib and lenalidomide, can be used as single agents or in combination with others. Bruton's tyrosine kinase (BTK) inhibitors including ibrutinib, acalaburtinib, and zanubrutinib have also been proven effective for the treatment of (R/R) disease. Another agent is Venetoclax, a robust drug that can be used in MCL after progression or intolerance to BTKi. Newer advances in the management of MCL have led to the utilization of cellular therapies including chimeric antigen receptor (CAR) T cell therapy and SCT that are options for healthy young (< 65 years old) who have progressed through several lines of therapies. With progression of disease, mutations are acquired that cause therapy resistance. Novel therapeutic agents such as non-covalent BTKis, bispecific antibodies, and antibody-drug conjugates are paving the way for advancements in treatment for R/R MCL. R/R MCL is a complex disease with many therapeutic options none of which has been proven superior in head-to-head comparison. In this review, the current treatment strategies are recapped, evolving agents are discussed, and we provide guidance in treating R/R MCL.
Authors: Jennifer Chapman-Fredricks; Jose Sandoval-Sus; Francisco Vega; Izidore S Lossos Journal: Ann Diagn Pathol Date: 2014-04-13 Impact factor: 2.090
Authors: Carlo Visco; Maria C Tisi; Andrea Evangelista; Alice Di Rocco; Anna-Katharina Zoellner; Vittorio R Zilioli; Stefan Hohaus; Roberta Sciarra; Alessandro Re; Cristina Tecchio; Annalisa Chiappella; Lucia Morello; Guido Gini; Luca Nassi; Tommasina Perrone; Anna L Molinari; Alberto Fabbri; Maria C Cox; Erica Finolezzi; Simone Ferrero; Benedetta Puccini; Isabel Alvarez De Celis; Annalisa Arcari; Dario Marino; Michele Merli; Francesco Piazza; Massimo Gentile; Matteo Pelosini; Giacomo Loseto; Olivier Hermine; Martin Dreyling; Marco Ruggeri; Maurizio Martelli; Eva Hoster; Umberto Vitolo Journal: Br J Haematol Date: 2018-11-08 Impact factor: 6.998
Authors: Eva Hoster; Andreas Rosenwald; Françoise Berger; Heinz-Wolfram Bernd; Sylvia Hartmann; Christoph Loddenkemper; Thomas F E Barth; Nicole Brousse; Stefano Pileri; Grzegorz Rymkiewicz; Roman Kodet; Stephan Stilgenbauer; Roswitha Forstpointner; Catherine Thieblemont; Michael Hallek; Bertrand Coiffier; Ursula Vehling-Kaiser; Réda Bouabdallah; Lothar Kanz; Michael Pfreundschuh; Christian Schmidt; Vincent Ribrag; Wolfgang Hiddemann; Michael Unterhalt; Johanna C Kluin-Nelemans; Olivier Hermine; Martin H Dreyling; Wolfram Klapper Journal: J Clin Oncol Date: 2016-02-29 Impact factor: 44.544
Authors: Preetesh Jain; Shaojun Zhang; Rashmi Kanagal-Shamanna; Chi Young Ok; Krystle Nomie; Graciela Nogueras Gonzalez; Omarya Gonzalez-Pagan; Holly A Hill; Hun Ju Lee; Luis Fayad; Jason Westin; Loretta Nastoupil; Frederick Hagemeister; Wendy Chen; Onyeka Oriabure; Maria Badillo; Changying Jiang; Yao Yixin; Shaoying Li; Guilin Tang; C Cameron Yin; Keyur P Patel; Leonard Jeffrey Medeiros; Ranjit Nair; Sairah Ahmed; Swaminathan P Iyer; Selvi Thirumurthi; Richard Champlin; Guofan Xu; Pan Tinsu; David Santos; Ruiping Wang; Guangchun Han; Jianhua Zhang; Xingzhi Song; Sattva Neelapu; Jorge Romaguera; Andy Futreal; Christopher Flowers; Nathan Fowler; Linghua Wang; Michael L Wang Journal: Blood Adv Date: 2020-03-24
Authors: Anita Kumar; Fushen Sha; Ahmed Toure; Ahmet Dogan; Andy Ni; Connie L Batlevi; Maria Lia M Palomba; Carol Portlock; David J Straus; Ariela Noy; Steven M Horwitz; Alison Moskowitz; Paul Hamlin; Craig H Moskowitz; Matthew J Matasar; Andrew D Zelenetz; Anas Younes Journal: Blood Cancer J Date: 2019-05-20 Impact factor: 11.037
Authors: Alessia Castellino; Yucai Wang; Melissa C Larson; Matthew J Maurer; Brian K Link; Umar Farooq; Andrew L Feldman; Sergei I Syrbu; Thomas M Habermann; Jonas Paludo; David J Inwards; Thomas E Witzig; Stephen M Ansell; Cristine Allmer; Susan L Slager; Jonathon B Cohen; Peter Martin; James R Cerhan; Grzegorz S Nowakowski Journal: Blood Adv Date: 2022-02-22